CDK4 and cancer: Currently, all three CDK4/6 inhibitors are approved (in combination with aromatase inhibitors) for the treatment of estrogen receptor-positive/HER2-negative metastatic breast cancer [186,187,188,189,190], and many clinical trials using these drugs are in progress for other types of cancer [191,192,193,194,195,196,197].